PRS AAPS Oral Proofs 2016
Eugenia H. Cho, BS, Ruya Zhao, BS, Rachel Greenup, MD, Scott T. Hollenbeck, MD, FACS
From the Duke University Medical Center, Durham, N.C.
PURPOSE: Patients considering breast implant augmentation (IA) fear that implant placement may impair the early detection of breast cancer and lead to worse prognosis. This study assessed whether breast IA is associated with more advanced breast tumors at the time of therapeutic mastectomy.
METHODS: Breast cancer stage distribution at diagnosis was retrospectively analyzed for 90 women with previous IA who underwent therapeutic mastectomy at a single institution from 1993 to 2014 (mean follow-up, 3.6 ± 3.6 years). Comparison was made with all women without IA undergoing therapeutic mastectomy at the same institution in 2010 (n = 171). Subanalyses were performed according to implant characteristics.
RESULTS: Ninety women with previous IA underwent mastectomy for 96 breast cancers at a mean interval of 15.4 ± 10.8 years after IA surgery. Mean age at cancer diagnosis was 52.4 ± 10.7 years. Compared with non-IA women, women with previous IA were leaner (P < 0.01) and more commonly white (P < 0.01). Breast cancer stage at diagnosis was similar for both groups (P = 0.28). Among IA patients, subglandular implants were associated with later stage breast cancers (P < 0.01) and detection by self-palpation (P = 0.04), compared with subpectoral implants.
CONCLUSIONS: This institutional study is the largest to assess breast cancer detection among women with previous IA according to implant characteristics. Breast cancer stage distribution did not differ for women with and without IA. In the IA cohort, women with subglandular implants presented with more advanced breast tumors in palpable form.